title: Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women.
abstract: The purpose of this study was to examine insulin resistance, markers of the metabolic syndrome, cardiovascular disease (CVD) risk, and serum adiponectin concentrations in pre-menopausal Hispanic and non-Hispanic White (NHW) women. This cross-sectional study examined 119 pre-menopausal women (76 Hispanic, 45 NHW) for markers of the metabolic syndrome (ATP III criteria), level of insulin resistance (HOMA-IR), CVD risk factors, and serum total adiponectin concentrations. Relationships between variables were assessed using Student's t-tests, Pearson's and Spearman's Rho correlations, and stepwise multiple regression analysis. Hispanic women had significantly lower adiponectin concentrations than NHW women, even after controlling for body fat (%) (P < 0.01). Number of markers of the metabolic syndrome was inversely related to total adiponectin concentration for all women combined and for NHW women (P ≤ 0.04), but not for Hispanic women. Insulin resistance was inversely related to adiponectin for all women and for NHW women (P < 0.01), but not significantly associated in Hispanic women. Adiponectin concentration was not significantly associated with number of CVD risk factors for these women. While adiponectin was associated with markers of metabolic syndrome and insulin resistance for all women of this study and despite lower adiponectin concentrations for Hispanic women than NHW women, the role of adiponectin to these conditions among Hispanics remains unclear. There was no significant association between adiponectin and CVD risk for these women. Future research should focus on understanding mechanisms for up-regulating adiponectin secretion and if ethnicity affects adiponectin gene expression and secretion given the beneficial effects derived from elevated adiponectin levels.
authors.affiliation: Department of Kinesiology, The University of Texas at El Paso, 1101 N Campbell St, El Paso, TX 79902, USA. gking@utep.edu
authors.forename: George A
authors.initials: GA
authors.lastname: King
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Deemer
authors.forename: Dixie L
authors.initials: DL
authors.lastname: Thompson
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology / Q000208:ethnology; D003430:Cross-Sectional Studies; D005260:Female; D006630:Hispanic or Latino; D006801:Humans; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000097:blood* / Q000453:epidemiology / Q000208:ethnology; D008875:Middle Aged; D012307:Risk Factors; D014481:United States / Q000453:epidemiology / Q000208:ethnology; D044465:White People
chemical_list: D052242:Adiponectin; D015415:Biomarkers
references.citation: Scand J Clin Lab Invest. 2007;67(5):449-58
references.pmid: 17763181
references.citation: JAMA. 2002 Jan 16;287(3):356-9
references.pmid: 11790215
references.citation: Metabolism. 2004 Jan;53(1):1-3
references.pmid: 14681833
references.citation: Timely Top Med Cardiovasc Dis. 2008 Feb 04;12:E3
references.pmid: 18392213
references.citation: Eur Heart J. 2005 Aug;26(16):1640-6
references.pmid: 15932907
references.citation: Ann Med. 2001 Nov;33(8):534-41
references.pmid: 11730160
references.citation: Int J Obes (Lond). 2008 May;32(5):740-8
references.pmid: 18180784
references.citation: Diabetes. 2008 Apr;57(4):980-6
references.pmid: 18192541
references.citation: Transl Res. 2007 Jun;149(6):317-23
references.pmid: 17543850
references.citation: J Clin Endocrinol Metab. 2005 Oct;90(10):5677-83
references.pmid: 16076942
references.citation: Am J Epidemiol. 2007 Jan 15;165(2):164-74
references.pmid: 17101706
references.citation: NCHS Data Brief. 2007 Nov;(1):1-8
references.pmid: 19389313
references.citation: Ann Intern Med. 2008 Sep 2;149(5):307-16
references.pmid: 18765700
references.citation: J Clin Endocrinol Metab. 2007 Jul;92(7):2665-71
references.pmid: 17426091
references.citation: Curr Opin Lipidol. 2002 Feb;13(1):51-9
references.pmid: 11790963
references.citation: Vasc Health Risk Manag. 2007;3(6):853-76
references.pmid: 18200806
references.citation: Am J Hum Genet. 2004 May;74(5):979-1000
references.pmid: 15088269
references.citation: Am J Cardiol. 2006 Dec 15;98(12):1603-8
references.pmid: 17145218
references.citation: Pharmacol Res. 2007 Dec;56(6):459-67
references.pmid: 18029194
references.citation: Circulation. 2003 Sep 30;108(13):1546-51
references.pmid: 14517150
references.citation: J Clin Endocrinol Metab. 2004 Jun;89(6):2595-600
references.pmid: 15181029
references.citation: JAMA. 2009 Jul 8;302(2):179-88
references.pmid: 19584347
references.citation: J Clin Invest. 2007 Sep;117(9):2621-37
references.pmid: 17717599
references.citation: Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):29-33
references.pmid: 14551151
references.citation: J Biol Chem. 1995 Nov 10;270(45):26746-9
references.pmid: 7592907
references.citation: J Clin Endocrinol Metab. 2008 Oct;93(10):4075-9
references.pmid: 18682512
references.citation: Nutr Rev. 2003 Aug;61(8):290-2
references.pmid: 13677592
references.citation: Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):e15-6
references.pmid: 15731480
references.citation: Circulation. 2004 Apr 20;109(15):1809-12
references.pmid: 15096460
references.citation: J Clin Endocrinol Metab. 2001 May;86(5):1930-5
references.pmid: 11344187
references.citation: Int J Obes (Lond). 2007 May;31(5):770-6
references.pmid: 17117187
references.citation: Diabetes Obes Metab. 2007 May;9(3):282-9
references.pmid: 17391153
references.citation: Diabetologia. 1985 Jul;28(7):412-9
references.pmid: 3899825